Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12621000896875
ACTRN12621000896875
Completed
未知

WITHDRAWal of heart failure directed therapies in recovered Atrial Fibrillation mediated cardiomyopathy- investigating the impact on left ventricular ejection fraction: the WITHDRAW-AF study

Alfred Hospital0 sites60 target enrollmentJuly 8, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsatrial fibrillationheart failureCardiovascular - Other cardiovascular diseases

Overview

Phase
未知
Intervention
Not specified
Conditions
atrial fibrillation
Sponsor
Alfred Hospital
Enrollment
60
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 8, 2021
End Date
June 3, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Alfred Hospital

Eligibility Criteria

Inclusion Criteria

  • •Age\>18 years
  • •\- AF mediated cardiomyopathy
  • •Previous LVEF \<40% in the setting of AF with recovery to \>50% within 6 months after
  • •restoration of sinus rhythm (with anti\-arrhythmic medications, electrical cardioversion,
  • •catheter ablation or any combination of these)
  • •\- NYHA class I
  • •\- Currently on pharmacological anti\-heart failure therapy including at least 2 of:
  • •\-ACE inhibitor or Angiotensin receptor antagonist
  • •\-Diuretic (excluding MRA)
  • •\-Cardiac specific beta blocker

Exclusion Criteria

  • •\- Patients with unsuccessful rhythm control
  • •\- Patients with known contributing cause of LV dysfunction including
  • •\-Ischaemic cardiomyopathy
  • •\-Valvular heart disease
  • •\-Hypertrophic cardiomyopathy
  • •\-Uncontrolled current/ongoing alcohol intake
  • •\-Other cause of cardiomyopathy (eg thyroid disease)
  • •\- Significant renal impairment (eGFR\<30mL/min/1\.73m2\)
  • •\- Contraindication to
  • •\-cardiac MRI,

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
ovel Interventions in Heart Failure with Preserved Ejection Fraction using TadalafilHeart Failure with Preserved Ejection FractionCardiovascular - Other cardiovascular diseases
ACTRN12612000684820South Australian Health and Medical Reseasrch Institute20
Not yet recruiting
Phase 4
ovel Interventions in Heart Failure with Preserved Ejection Fraction using ivabradineHeart Failure with Preserved Ejection FractionCardiovascular - Other cardiovascular diseases
ACTRN12612000710820South Australian Health and Medical Research Institute20
Recruiting
Phase 2
Beta-Blocker Withdrawal in Heart Failure with Preserved Ejection Fraction and Chronotropic Incompetence (BRILLIANT)
JPRN-jRCT1031210030Obokata Masaru150
Not yet recruiting
Not Applicable
Clinical study on intervention of heart failure patients after myocardial infarction with Wuqinxi based on the theory of ''supporting yang''Postinfarction heart failure
ITMCTR2022000105Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Completed
Not Applicable
The development of the treatment for heart failure using non-pulsatile Left ventricle assist deviceEnd-staged dilated cardiomyopathy and ischemic cardiomyopathy who receive Left ventricle assist devise
JPRN-UMIN000003665Medical Center for Translational Research, Osaka University Hospital10